UNI-EN 88:Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 88 | / | 2022 | |||||||
| Date of issue: | 2022-11-29 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| “Sopharma” AD (the Company) announces that today, according to a decision of the Board of Directors dated November 28, 2022, the company concluded the following transaction falling within the scope of Art. 114, para. 2 of the LPOS: 1. “Sopharma” AD as a Lessee, concluded Annex № 1 to the Lease Agreement dated March 1, 2022 with “Sopharma Imoti” REIT, UIC 175059266. A) Participation of interested parties: Bissera Lazarova is an interested person, as on the one hand she is a member of the management body (Board of Directors) of the public company “Sopharma” AD, and on the other hand she is a member of the management body (Board of Directors) of the opposite party on the transaction - grounds for interest under Art. 114, para. 7, item 3 of the LPOS; B) Value of the transaction: Pursuant to Art. 114a, para. 5 of the LPOS the value of the property provided for use under the contract is determined between the higher of its market value and its value according to the last audited financial statements, which is publicly disclosed, in view of which the Board of Directors has adopted property, namely an amount in the total amount of BGN 8,150 (eight thousand one hundred and fifty leva), as the assessment is based on a special assessment dated October 10, 2022 for the market value of real estate, prepared by independent licensed appraisers - consultants to “Acticon” OOD, Sofia, with UIC 131359011 and presented by the Landlord – “Sopharma Imoti” REIT. Lease term: 9 years and 2 months (for the remaining term of the Contract until 01.03.2032); Rental area: 15.76 sq.m.; Rental price: 4.85 euros per sq.m. per month, without VAT. C) Assessment of the applicability of the conditions under Art. 114, para. 1, item 1 of the LPOS: Тhe value of the described transaction does not exceed the threshold under Art. 114, para. 1, item 1 b. b) of the LPOS, due to which the transaction falls within the scope of Art. 114, para. 2 of LPOS and for its conclusion prior approval has been received by the Board of Directors of „Sopharma“ AD. D) Assessment of the applicability of Art. 114 para. 6 of LPOS: With regard to this transaction, the hypothesis of Art. 114 para. 6 of the LPOS is not applicable. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_29112022_SopharmaImoti_114_espi.pdf SFA_29112022_SopharmaImoti_114_espi.pdf | Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2022-11-29 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 9.8 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
